{"id":40908,"date":"2021-07-01T06:24:17","date_gmt":"2021-07-01T06:24:17","guid":{"rendered":"https:\/\/i-base.info\/htb\/?p=40908"},"modified":"2021-07-03T11:53:16","modified_gmt":"2021-07-03T11:53:16","slug":"covid-19-treatment-tofacitinib-regn-bnabs-convalescent-plasma","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/40908","title":{"rendered":"COVID-19 treatment: tofacitinib, REGN bNAbs, convalescent plasma"},"content":{"rendered":"
\n

Simon Collins, HIV i-Base<\/strong><\/p>\n

<\/span><\/strong><\/p>\n

The following brief reports are significant for COVID-19 treatment. Please refer to the online papers for context and full details.<\/strong><\/p>\n

Tofacitinib<\/h2>\n<\/div>\n
\n

A randomised placebo-controlled study in 289 participants hospitalised with COVID-19 pneumonia in Brazil reported reduced risk of mortality using the JAK inhibitor tofacitinib.<\/span><\/p>\n<\/div>\n

\n

\u201cThe cumulative incidence of death or respiratory failure through day 28 was 18.1% in the tofacitinib group and 29.0% in the placebo group (risk ratio, 0.63; 95% CI: 0.41 to 0.97; p=0.04). Death from any cause through day 28 occurred in 2.8% vs 5.5% of the active vs placebo groups (hazard ratio 0.49; 95% CI: 0.15 to 1.63).\u201d<\/span><\/p>\n<\/div>\n

\n

Participants receiving tofacitinib also had significantly improved outcomes on an 8-point ordinal scale. Adverse events were similar in each group (14% vs 12%).<\/span><\/p>\n<\/div>\n

\n

Ref: Guimar\u00e3es PO et al. \u00a0for the STOP-COVID Trial. Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia. NEJM. <\/span>DOI: 10.1056\/NEJMoa2101643. (16 June 2021).
\nhttps:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2101643<\/a><\/p>\n<\/div>\n

\n

REGN dual bNAbs: casirivimab and imdevimab<\/span><\/p>\n<\/div>\n

\n

The UK RECOVERY study report a mortality benefit using REGN dual bNAbs in people hospitalised with COVID-19, but only in the 30% who were seronegative at baseline.<\/span><\/p>\n<\/div>\n

\n

\u201c<\/span>In the primary efficacy population of seronegative patients, 396\/1633 (24%) vs 451\/150 (30%) died within 28 days in the REGN-COV vs standard of care arms respectively<\/span> (rate ratio 0.80; 95% CI: 0.70 to 0.91; p=0\u00b70010).<\/p>\n<\/div>\n

\n

Overall, (regardless of baseline antibody status), the results were 944\/4839 (20%) vs 1026\/4946 (21%) respectively (rate ratio 0.94; 95% CI: 0.86 to 1.03; p=0\u00b717).<\/span><\/p>\n<\/div>\n

\n

Ref: RECOVERY Study. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. MedRxiv. Pre-peer review. doi: 10.1101\/2021.06.15.21258542. (15 June 2021).
\n<\/span>https:\/\/www.medrxiv.org\/content\/10.1101\/2021.06.15.21258542v1<\/a><\/p>\n<\/div>\n

<\/div>\n
\n

Convalescent plasma<\/h2>\n

No impact of convalescent plasma (CP) was found on 30-day mortality in participants with mild or moderate COVID-19 using date from an observational cohort from the Veteran\u2019s Affairs (VA).<\/span><\/p>\n<\/div>\n

\n

Based on approximately 400 participants using CP and >10,000 controls, there were 40 vs 671 deaths, respectively. Mortality was 6.5% vs 6.2%, with a risk difference of 0.30% (95% CI: 2.30 to 3.60) and hazard ratio of 1.04 (95% CI: 0.64 to 1.62).<\/span><\/p>\n<\/div>\n

\n

Ref: Cho K et al. Early convalescent plasma therapy and mortality among US veterans hospitalized with non-severe COVID-19: An observational analysis emulating a target trial. JID, DOIj:10.1093\/infdis\/jiab330. (21 June 2021).
\n<\/span>https:\/\/doi.org\/10.1093\/infdis\/jiab330<\/a><\/p>\n<\/div>\n

\n

\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"

Simon Collins, HIV i-Base The following brief reports are significant for COVID-19 treatment. Please refer to the online papers for context and full details. Tofacitinib A randomised placebo-controlled study in 289 participants hospitalised with COVID-19 pneumonia in Brazil reported reduced …<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[283,278],"tags":[],"class_list":["post-40908","post","type-post","status-publish","format-standard","hentry","category-covid-19-investigational-drugs","category-covid-19"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/40908","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=40908"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/40908\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=40908"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=40908"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=40908"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}